Angiotensin Converting Enzyme Inhibitors

Angiotensin II is a very potent chemical that causes the muscles surrounding blood vessels to contract, thereby narrowing the vessels. The narrowing of the vessels increases the pressure within the vessels causing high blood pressure (hypertension). Angiotensin II is formed from angiotensin I in the blood by the enzyme angiotensin converting enzyme (ACE). ACE inhibitors are medications that slow (inhibit) the activity of the enzyme ACE, which decreases the production of angiotensin II. As a result, the blood vessels enlarge or dilate, and blood pressure is reduced. This lower blood pressure makes it easier for the heart to pump blood and can improve the function of a failing heart. In addition, the progression of kidney disease due to high blood pressure or diabetes is slowed.
ACE inhibitors are used for controlling blood pressure, treating heart failure, preventing strokes, and preventing kidney damage in people with hypertension or diabetes. They also improve survival after heart attacks. Because they prevent early death resulting from hypertension, heart failure or heart attacks, ACE inhibitors are one of the most important group of drugs. This new book presents important research in this field.

Table of Contents:
Preface

1. Angiotensin Converting Enzyme Inhibitors
(Macaulay A. C. Onuigbo, Assistant Professor of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, Nnonyelum T. C. Onuigbo, Architect/Data Base Analysrt/Programmer, Information Technologies, NTec Solutions LLC, Eau Claire, WI) pp. 1-41

2. Adverse Effects of Angiotensin-Converting Enzyme Inhibitor: A Review of the Literature and Case Report
(Hiromichi Yoshida, Dept. of Internal Medicine, San-ai Memorial Hospital, Chiba, Japan, Shigeru Hasegawa, Dept. of Nephrology, Chiba Social Insurance Hospital, Chiba, Japan, Yasubumi Irie, Dept. of Internal Medicine, San-ai Memorial Hospital, Chiba, Japan) pp. 43-62

3. Plant-Derived Substances as ACE inhibitors
(Ingrid A-L Persson, Karin Persson, Dept. of Medicinal and Health Sciences, Divisioin of Drug Research/Pharmacology, Faculty of Health Sciences, Linkoping Univ., Sweden) pp. 63-93

4. The Proper Use of Angiotensin-Covering Enzyme Inhibitors in Patients with Chronic Kidney Disease
(Hiroshi Nonoguchi, Division of Kidney and Dialysis, Dept. of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, Takeaki Inoue, Dept. of Nephrology, Kumamoto Univ. Graduate School of Medicine Sciences, Kumamoto, Japan, Yushi Nakayama, Dept. of Nephrology, Kumamoto Univ. Graduate School of Medicine Sciences, Kumamoto, Japan, Yuichiro Izumi, Dept. of Nephrology, Kumamoto Univ. Graduate School of Medicine Sciences, Kumamoto, Japan, Takeshi Nakanishi, Division of Kidney and Dialysis, Dept. of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan) pp. 95-112

5. Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function
(Fadi Alqaisi, Mouaz H. Al-Mallah, FACC, Henry Ford Heart and Vascular Inst., Detroit, MI) pp. 113-128

6. Dual Blockade of the Renin-Angiotensin System: Angiotensin Converting Enzyme Inhibition, Angiotensin Receptor Blockade and Renin Inhibitor
(George S. Stergiou, Efthimia G. Nasothimiou, Hypertension Center, Third Univ. Dept. of Medicine, Sotiria Hospital, Athens, Greece) pp. 129-146

7. Angiotensin-Converting Enzyme Inhibitors in Patients with
Bilateral Atherosclerotic Renal Artery Stenosis
(Sarabjeet Singh, Bipin Thapa, Roopashree Prabhu, Rohit Arora, Sandeep Khosla, Section of Cardiology, Department of Medicine, Rosalind Franklin University of Medicine & Science/ The Chicago Medical School, North Chicago, and Mount Sinai Hospital, Chicago, Illinois) pp. 147-161

8. Angiotensin Converting Enzyme Inhibitors in Renal Disease
(Nicolas Roberto Robles, Unidad de Hipertension, Servicio de Nefrologia, Hospital Infanta Cristina, Badajoz, Spain) pp. 163-184

9. Kallikrein-Kinin Pathways in Mediate the Hypotensive Action of Angiotensin Converting Enzyme (ACE) Inhibitors
(J. N. Sharma, Dept. of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwaut Univ. Safat, Kuwait) pp. 185-198

10. Angiotensin Converting Enzyme Inhibitors: Improving Utilization and Adherence
(Micah L. Thorp, Lake Road Nephrology Center, Kaiser Kidney Program, Kaiser Permanente Northwest, Milwaukie, Ore) pp. 199-210

11. Angiotensin Blockade in Pediatric Chronic Kidney Disease
(Lavjay Butani, Section of Pediatric Nephrology, Univ. of California Davis Medical Center, Sacramento, CA) pp. 211-217

Index